Free Newsletter
Seattle Genetics pockets milestone
A recent INDA from Genentech triggered a milestone payment to Seattle Genetics. In their collaboration, Genentech uses Seattle Genetics' drug conjugates to improve the potency of a therapy. The amount of the milestone was undisclosed. Release
Comments (1) | Post a comment
Comments
By Gail Gillenwater | Posted 7:26pm | June 18, 2008
John,
Today's SPOTLIGHT included an error concerning a regulatory abbreviation. IND is the abbreviation for investigational new drug application [see 21 CFR 312.3(b)]. Consequently, INDA would mean investigational new drug application application.
You do a great job and I thought the above would be of interest to you.
Best regards,
Gail
Gail E. Gillenwater, Ph.D.
Principal
Pharma Development Solutions
Seattle, WA
